-
公开(公告)号：US06228641B1
公开(公告)日：2001-05-08
申请号：US09081345
申请日：1998-05-19
申请人： Bahija Jallal , Gregory D. Plowman
发明人： Bahija Jallal , Gregory D. Plowman
IPC分类号： C12N510
CPC分类号： C12N9/1205 , C07K14/705 , C07K2319/00 , C12N9/16
摘要： The present invention relates to PTP04 polypetides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP04 related diseases or conditions characterized by an abnormal interaction beteeen a PTP04 polypeptide and a PTP04 binding partner.
摘要翻译： 本发明涉及PTP04多聚体，编码这样的多肽的核酸，含有这种核酸的细胞，组织和动物，这种多肽的抗体，利用这些多肽的测定法，以及与所有上述相关的方法。 提供治疗，诊断和筛选方法，用于PTP04相关疾病或特征为PTP04多肽与PTP04结合配偶体之间异常相互作用的病症。
-
公开(公告)号：US07115710B2
公开(公告)日：2006-10-03
申请号：US09095478
申请日：1998-06-10
申请人： Gregory D. Plowman , Bahija Jallal
发明人： Gregory D. Plowman , Bahija Jallal
IPC分类号： C07K14/00 , C07K14/435
CPC分类号： C12N9/1205 , C07K14/705 , C07K16/40 , C07K2319/00 , C12N9/16 , Y10S530/828 , Y10S530/829
摘要： The present invention relates to PTP05 polypeptides and PTP10 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP05 and/or PTP10 related diseases or conditions characterized by an abnormal interaction between a PTP05 polypeptide and a PTP05 binding partner and/or a PTP10 polypeptide and a PTP10 binding partner.
摘要翻译： 本发明涉及PTP05多肽和PTP10多肽，编码此类多肽的核酸，含有此类核酸的细胞，组织和动物，此类多肽的抗体，利用此类多肽的测定法以及与上述所有相关的方法。 提供用于PTP05和/或PTP10相关疾病或特征为PTP05多肽与PTP05结合配偶体和/或PTP10多肽和PTP10结合配偶体之间异常相互作用的病症的治疗，诊断和筛选方法。
-
公开(公告)号：US06844177B2
公开(公告)日：2005-01-18
申请号：US09822295
申请日：2001-04-02
申请人： Bahija Jallal , Gregory D. Plowman
发明人： Bahija Jallal , Gregory D. Plowman
IPC分类号： C07K14/705 , C12N9/12 , C12N9/16 , A61K38/45 , C07K7/04 , C07K14/435
CPC分类号： C12N9/1205 , C07K14/705 , C07K2319/00 , C12N9/16
摘要： The present invention relates to PTP04 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animal containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP04 related diseases or conditions characterized by an abnormal interaction between a PTP04 binding partner.
摘要翻译： 本发明涉及PTP04多肽，编码此类多肽的核酸，含有此类核酸的细胞，组织和动物，对此类多肽的抗体，利用此类多肽的测定法以及与上述所有相关的方法。 提供治疗，诊断和筛选方法，用于PTP04相关疾病或特征为PTP04结合配偶体之间异常相互作用的病症。
-
4.发明申请METHODS FOR DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISORDERS MEDIATED BY CD40 SIGNALING 失效诊断和治疗CD40信号传导的增殖性疾病的方法公开(公告)号：US20090041773A1
公开(公告)日：2009-02-12
申请号：US11914714
申请日：2006-05-18
IPC分类号： A61K39/395 , G01N33/574 , C12Q1/68 , C12Q1/37 , A61P31/00 , C12Q1/18 , G01N33/53
CPC分类号： G01N33/6863 , A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K2317/21 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C12Q1/6886 , G01N33/5091 , G01N33/574 , G01N2333/70575
摘要： Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
摘要翻译： 提供了用于鉴定将受益于调节CD40L介导的CD40信号传导的抗CD40治疗剂的癌症或恶性前病症的受试者的方法。 该方法包括使用细胞凋亡，细胞增殖和存活的生物标志物，以及CD40信号通路来监测对调节表达CD40的肿瘤细胞上的CD40信号传导的一种或多种感兴趣的抗CD40治疗剂的离体反应。 离体预后测定可以单独使用或与其他预后测定结合使用，以鉴定将受益于抗CD40治疗剂治疗的候选受试者。 本发明的方法还包括使用这些生物标志物来监测用抗CD40治疗剂治疗的体内功效。
-
公开(公告)号：US20060019305A1
公开(公告)日：2006-01-26
申请号：US11197489
申请日：2005-08-05
申请人： Gregory Plowman , Bahija Jallal
发明人： Gregory Plowman , Bahija Jallal
CPC分类号： C12N9/1205 , C07K14/705 , C07K16/40 , C07K2319/00 , C12N9/16 , Y10S530/828 , Y10S530/829
摘要： The present invention relates to PTP05 polypeptides and PTP10 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP05 and/or PTP10 related diseases or conditions characterized by an abnormal interaction between a PTP05 polypeptide and a PTP05 binding partner and/or a PTP10 polypeptide and a PTP10 binding partner.
-
6.发明授权公开(公告)号：US07871786B2
公开(公告)日：2011-01-18
申请号：US12232134
申请日：2008-09-11
IPC分类号： G01N33/53 , A61K39/395 , C07K16/00 , C07K5/00
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4702 , C07K14/82 , C07K16/18 , C07K16/40
摘要： The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
摘要翻译： 本发明涉及通过检测鸟嘌呤核苷酸交换因子生物标记（例如新型GEF-H1S）的磷酸变异同种型来诊断生物样品中的异常细胞增殖并筛选抑制，减少或消除细胞生长，特别是致瘤细胞生长的药物 。
-
7.发明申请Methods for Diagnosis and Treatment of Diseases Having an Autoimmune and/or Inflammatory Component 有权具有自身免疫和/或炎症成分的疾病的诊断和治疗方法公开(公告)号：US20080274118A1
公开(公告)日：2008-11-06
申请号：US11914710
申请日：2006-05-18
IPC分类号： A61K39/395 , G01N33/567 , A61P1/00 , A61P3/00 , A61P19/00 , A61P29/00 , A61P37/00 , A61P25/00
CPC分类号： G01N33/564 , G01N33/5091 , G01N33/533 , G01N33/57484 , G01N33/582 , G01N2800/24 , G01N2800/52
摘要： Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
摘要翻译： 提供了用于鉴定将受益于调节CD40L介导的CD40信号传导的抗CD40治疗剂的炎性疾病和/或自身免疫性疾病的受试者的方法。 所述方法包括使用细胞凋亡，细胞增殖和存活的生物标志物，以及CD40信号通路来监测对一种或多种调节CD40表达细胞上的CD40信号传导的抗CD40治疗剂的离体反应。 离体预后测定可以单独使用或与其他预后测定结合使用，以鉴定将受益于抗CD40治疗剂治疗的候选受试者。 本发明的方法还包括使用这些生物标志物来监测用抗CD40治疗剂治疗的体内功效。
-
8.发明授权Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease 有权监测抗CD40抗体在治疗具有炎性或自身免疫疾病的受试者中的功效的方法公开(公告)号：US08333970B2
公开(公告)日：2012-12-18
申请号：US11914710
申请日：2006-05-18
IPC分类号： A61K39/395 , C12Q1/00 , C12Q1/68 , G01N33/53
CPC分类号： G01N33/564 , G01N33/5091 , G01N33/533 , G01N33/57484 , G01N33/582 , G01N2800/24 , G01N2800/52
摘要： Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
摘要翻译： 提供了用于鉴定将受益于调节CD40L介导的CD40信号传导的抗CD40治疗剂的炎性疾病和/或自身免疫性疾病的受试者的方法。 所述方法包括使用细胞凋亡，细胞增殖和存活的生物标志物，以及CD40信号通路来监测对一种或多种调节CD40表达细胞上的CD40信号传导的抗CD40治疗剂的离体反应。 离体预后测定可以单独使用或与其他预后测定结合使用，以鉴定将受益于抗CD40治疗剂治疗的候选受试者。 本发明的方法还包括使用这些生物标志物来监测用抗CD40治疗剂治疗的体内功效。
-
9.发明申请ANTI-ICOS ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE 审中-公开抗ICOS抗体及其在治疗肿瘤，移植和自发性疾病中的应用公开(公告)号：US20110243929A1
公开(公告)日：2011-10-06
申请号：US12971469
申请日：2010-12-17
申请人： Anthony COYLE , Yihong Yao , Bahija Jallal , Gianluca Carlesso , Michael Bowen
发明人： Anthony COYLE , Yihong Yao , Bahija Jallal , Gianluca Carlesso , Michael Bowen
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2818 , C07K2317/41 , C07K2317/56 , C07K2317/72 , C07K2317/732
摘要： The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
摘要翻译： 本发明提供具有增强的效应子功能的抗人ICOS抗体。 本发明进一步涉及药物组合物，免疫治疗组合物和使用结合人ICOS抗原并可能介导ADCC，CDC和/或抗体依赖性吞噬作用（调理作用）的治疗性抗体的治疗和预防T细胞 - 介导的疾病和病症，例如但不限于慢性感染，自身免疫疾病或病症，炎性疾病或病症，移植物抗宿主病（GVHD），移植排斥反应和T细胞增殖性疾病。
-
10.发明申请公开(公告)号：US20090130695A1
公开(公告)日：2009-05-21
申请号：US12232134
申请日：2008-09-11
IPC分类号： G01N33/574 , G01N33/536 , G01N33/53
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4702 , C07K14/82 , C07K16/18 , C07K16/40
摘要： The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
摘要翻译： 本发明涉及通过检测鸟嘌呤核苷酸交换因子生物标记（例如新型GEF-H1S）的磷酸变异同种型来诊断生物样品中的异常细胞增殖并筛选抑制，减少或消除细胞生长，特别是致瘤细胞生长的药物 。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.029 秒)